Matrix metalloproteinase-9 in the ventricular cerebrospinal fluid correlated with the prognosis of traumatic brain injury

Turk Neurosurg. 2014;24(3):363-8. doi: 10.5137/1019-5149.JTN.8551-13.0.

Abstract

Aim: Matrix metalloproteinase 9 (MMP-9) has been shown to be a potential biomarker for outcome prediction after neuron damage. This study investigated whether MMP-9 could be used for outcome prediction after traumatic brain injury (TBI).

Material and methods: For the TBI group, cerebrospinal fluid (CSF) was collected at different days after surgery from 6 head injury patients who had received surgical intervention with external ventricular drainage insertion. CSF collected from non-TBI patients (N=85) diagnosed with isolated hydrocephalus by a ventricular puncture during a ventriculo-peritoneal shunt surgery was used as control.

Results: The mean concentration of MMP-9 in the CSF of 85 non-TBI patients was determined to be 1.172 ± 0.859 ng/mL. We found that the CSF MMP-9 concentration from TBI patients was elevated immediately after head injury with a median of 1.926 ng/mL (range, 0.673 to 24.990). Despite an early increase in the concentration of MMP-9, levels decreased within 72 hrs and nearly reached the normal range. Nevertheless, the concentration of MMP-9 was negatively correlated with the Glasgow Coma Scale (γ = - 0.337, p = 0.013).

Conclusion: MMP-9 concentration in the CSF of TBI patients correlated with neurological outcome and may represent an early indicator for the prognosis of this condition.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / cerebrospinal fluid
  • Brain Injuries / cerebrospinal fluid*
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Female
  • Glasgow Coma Scale
  • Humans
  • Infant
  • Male
  • Matrix Metalloproteinase 9 / cerebrospinal fluid*
  • Middle Aged
  • Prognosis
  • Young Adult

Substances

  • Biomarkers
  • MMP9 protein, human
  • Matrix Metalloproteinase 9